What do systematic reviews say?

Dornase alfa vs dornase alfa and mannitol

Dornase alfa may leads to higher change in quality of life ‐ CFQ‐R at 3 months compared with dornase alfa and mannitol (low certainty).

• Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
  MD 10.61 [0.27, 20.95]
  231 participants
  Low

Dornase alfa vs placebo or no dornase alfa treatment

Dornase alfa showed no clear difference in change in quality of life ‐ CFQ‐R respiratory at 1 month compared with placebo or no dornase alfa treatment (low certainty).

• Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
  MD 0.84
  19 participants
  Low
• Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
  MD 9.78
  19 participants
  Low

Dornase alfa vs mannitol

Dornase alfa may leads to higher change in quality of life ‐ CFQ‐R at 3 months compared with mannitol (low certainty).

• Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
  MD 10.61 [0.27, 20.95]
  231 participants
  Low

Dornase alfa vs hypertonic saline

Dornase alfa showed no clear difference in mean relative percentage in quality of life score at 3 months compared with hypertonic saline (low certainty).

• Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
  MD 0.03
  431 participants
  Low

Dornase alfa vs alternate days

Dornase alfa daily showed no clear difference in mean relative percentage in quality of life score at 3 months compared with alternate days (low certainty).

• Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
  MD 0.01
  43 participants
  Low

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD

The review found no eligible studies for this question.

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ nebulisers for delivering colistin and dornase alfa: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM)

The review found no eligible studies for this question.

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs VMT

• Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 85 participants
  Very low